Inventory of multinational pharmaceutical companies in 2020: Johnson & Johnson firmly ranks C, Novartis's pharmaceutical business is No. 1 in the world, and Humira is still the "king"

Conversion unit: 1 euro ≈ 1.

Conversion unit: 1 euro ≈ 1.

Conversion unit: 1 euro ≈ 1.
1891 US dollars, 1 pound ≈ 1.
3881 US dollars, 1 Swiss franc ≈ 1.
0755 US dollars, 1 Japanese yen ≈ 0.
00922 US dollars

It is worth mentioning that AbbVie's Humira will continue to perform well in 2020
.
This product has been the world’s best-selling drug "throne" for many consecutive years since 2012.
Due to the significant decline in sales growth in recent years, there is a view that Xiu Meile may soon give way to the "throne" of Merck.
K medicine"
.
However, judging from the financial reports of multinational pharmaceutical companies in 2020, Xiu Meile is still the "king", leading the sales of "K medicine" by more than 4 billion
.

Affected by the acquisition of Xinji, BMS owns the anti-tumor drug Revlimid developed by the former, and its sales volume in 2020 ranks third in the world
.
So far, BMS has become a pharmaceutical "player" with three sales of over US$5 billion
.

Revenue ranking of multinational pharmaceutical companies in China

Conversion unit: 1 euro ≈ 1.
1891 US dollars, 1 pound ≈ 1.
3881 US dollars, 1 Swiss franc ≈ 1.
0755 US dollars

Judging from the existing data, despite the impact of the epidemic in 2020 and the price cuts in medical insurance negotiations, China is still the target market for multinational pharmaceutical companies to continue to increase.
Except Sanofi, other multinational pharmaceutical companies have an average revenue in China.
With different degrees of improvement, AstraZeneca is still the "king"
.